MEK inhibitor trametinib in combination with gemcitabine regresses a patient-derived orthotopic xenograft (PDOX) pancreatic cancer nude mouse model
- 1 June 2018
- journal article
- research article
- Published by Elsevier in Tissue and Cell
- Vol. 52, 124-128
Abstract
No abstract availableKeywords
This publication has 42 references indexed in Scilit:
- Increased Survival in Pancreatic Cancer with nab-Paclitaxel plus GemcitabineNew England Journal of Medicine, 2013
- A phase 1b study of trametinib, an oral Mitogen-activated protein kinase kinase (MEK) inhibitor, in combination with gemcitabine in advanced solid tumoursEuropean Journal of Cancer, 2013
- FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic CancerNew England Journal of Medicine, 2011
- Drug Combination Studies and Their Synergy Quantification Using the Chou-Talalay MethodCancer Research, 2010
- Mechanisms of drug combinations: interaction and network perspectivesNature Reviews Drug Discovery, 2009
- Multi-target therapeutics: when the whole is greater than the sum of the partsDrug Discovery Today, 2007
- Strategies for optimizing combinations of molecularly targeted anticancer agentsNature Reviews Drug Discovery, 2006
- Multicomponent therapeutics for networked systemsNature Reviews Drug Discovery, 2005
- A new patient‐like metastatic model of human lung cancer constructed orthotopically with intact tissue via thoracotomy in immunodeficient miceInternational Journal of Cancer, 1992
- Models of human metastatic colon cancer in nude mice orthotopically constructed by using histologically intact patient specimens.Proceedings of the National Academy of Sciences, 1991